글로벌 연구동향
분자영상 및 방사화학
- 2016년 09월호
[Biomaterials. ]A novel small-molecule PPI inhibitor targeting integrin αvβ3-osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice.이화여대, 호서대/ 박두리, 이수영*, 강인철*
- 출처
- Biomaterials.
- 등재일
- 2016 Aug
- 저널이슈번호
- 98:131-42. doi: 10.1016/j.biomaterials.2016.05.007. Epub 2016 May 5.
- 내용
Abstract
Small molecule-inhibition targeting protein-protein interaction (PPI) is now recognized as an emerging and challenging area in drug design. We developed a novel interactive drug discovery methodology known as Protein Chip technology (ProteoChip) as a cutting-edge PPI assay system applicable for unique PPI-targeting therapeutics integrated with computer-aided drug design (CADD). Here, we describe a novel small molecular PPI inhibitor, IPS-02001, which the blocks integrin αvβ3-osteopontin interface a novel PPI inhibitor identified by the interactive methodology of both ProteoChip- and CADD-based PPI assay. IPS-02001 (6,7-Dichloro-2,3,5,8-tetrahydroxy-1,4-naphthoquinone) was screened from different compound libraries (InterBioScreen, Commercial libraries) using an in silico structure-based molecular docking simulation method and a protein chip-based protein-protein interaction assay system. Additionally, integrin αvβ3, an adhesion receptor expressed in osteoclasts (OCs), was implicated in the regulation of OC function via regulation of the cytoskeletal organization of OCs. IPS-02001 blocked OC maturation from murine bone marrow-derived macrophages, as well as the resorptive function of OCs. Moreover, treatment with IPS-02001 impaired downstream signaling of integrin αvβ3 linked to Pyk2, c-Src, PLCγ2, and Vav3 and disrupted the actin cytoskeleton in mature OCs. Furthermore, IPS-02001 blocked RANKL-induced bone destruction by reducing the number of OCs and protected against ovariectomy-induced bone loss in mice. Thus, IPS-02001 may represent a promising new class of anti-resorptive drugs for treatment of bone diseases associated with increased OC function.
Author information
Park D1, Park CW2, Choi Y2, Lin J1, Seo DH3, Kim HS3, Lee SY4, Kang IC5.
1Department of Life Science and the Research Center for Cellular Homeostasis, Ewha Womans University, Seoul 120-750, South Korea.
2BioChip Research Center, Hoseo University, Asan 336-795, South Korea.
3Department of Biomedical Engineering, Yonsei University, Wonju 220-710, South Korea.
4Department of Life Science and the Research Center for Cellular Homeostasis, Ewha Womans University, Seoul 120-750, South Korea. Electronic address: leesy@ewha.ac.kr.
5BioChip Research Center, Hoseo University, Asan 336-795, South Korea; Department of Biological Science, College of Natural Science and Hoseo University, Asan 336-795, South Korea; InnoPharmaScreen Inc., Asan 336-795, South Korea. Electronic address: ickang@hoseo.edu.
- 키워드
- Bone resorption; In silico molecular docking simulation; Integrin α(v)β(3)-OPN interface; Osteoclast inhibition; ProteoChip; Small-molecule PPI inhibitor
- 덧글달기
- 이전글 [J Control Release.] Prussian blue/serum albumin/indocyanine green as a multifunctional nanotheranostic agent for bimodal imaging guided laser mediated combinatorial phototherapy.
- 다음글 [J Control Release.] Dual CD44 and folate receptor-targeted nanoparticles for cancer diagnosis and anticancer drug delivery.
편집위원
뼈질병 관련 치료를 위한 새로운 protein-protein interaction (PPI) inhibitor인 IPS-02001을 Protein Chip (ProteoChip) 및 CADD 기반 PPI 방법으로 찾아내어 그 효과를 확인한 논문이다.
덧글달기닫기2016-09-02 10:26:20
등록